公开(公告)号：US20240271093A1

公开(公告)日：2024-08-15

申请号：US18629323

申请日：2024-04-08

申请人： Targazyme, Inc.

发明人： Stephen D. Wolpe ,  Leonard Miller ,  Lynnet Koh ,  Thomas E. Ichim

IPC分类号： C12N5/0783 ,  A61K35/12 ,  A61K35/17 ,  C12N5/00 ,  C12N5/0775 ,  C12N5/0789 ,  C12N5/0797

CPC分类号： C12N5/0638 ,  A61K35/17 ,  C12N5/0006 ,  C12N5/0623 ,  C12N5/0637 ,  C12N5/0647 ,  C12N5/0663 ,  C12Y204/01065 ,  A61K35/12 ,  A61K2035/124 ,  C12N2501/70 ,  C12N2501/724

摘要： Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.

公开(公告)号：US20240269188A1

公开(公告)日：2024-08-15

申请号：US18390569

申请日：2023-12-20

申请人： Rutgers, The State University of New Jersey

发明人： Yufang Shi ,  Guangwen Ren ,  Liying Zhang

IPC分类号： A61K35/28 ,  A61K35/12 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K45/06 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  C07K14/495 ,  C07K14/50 ,  C07K14/52 ,  C07K14/525 ,  C07K14/545 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C12N5/00 ,  C12N5/074 ,  C12N5/0775

CPC分类号： A61K35/28 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/191 ,  A61K38/20 ,  A61K38/2006 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  A61P37/04 ,  A61P37/06 ,  C12N5/0018 ,  C12N5/0607 ,  C12N5/0662 ,  C12N5/0663 ,  C12N5/0665 ,  A61K2035/122 ,  A61K45/06 ,  A61P37/02 ,  C07K14/495 ,  C07K14/50 ,  C07K14/52 ,  C07K14/525 ,  C07K14/545 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C12N2500/05 ,  C12N2501/10 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/2301 ,  C12N2501/2317 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2502/1114

摘要： The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

公开(公告)号：US20240269187A1

公开(公告)日：2024-08-15

申请号：US18628251

申请日：2024-04-05

申请人： The General Hospital Corporation d/b/a Massachusetts General Hospital ,  Dana-Farber Cancer Institute, Inc.

发明人： Anne Fletcher ,  Shannon J. Turley ,  Biju Parekkadan

IPC分类号： A61K35/26 ,  A61K35/12 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  C12N5/077 ,  C12N5/078

CPC分类号： A61K35/26 ,  C12N5/0651 ,  C12N5/0669 ,  A61K2035/122 ,  A61K38/1866 ,  A61K38/19 ,  A61K38/204

摘要： A method for suppressing an immune response is provided. The method involves administration of isolated lymphoid tissue-derived suppressive stromal cells (LSSC) to a subject in need of such treatment in an amount effective to suppress the immune response in the subject. The invention also involves a method to isolate LSSC by digesting lymphoid tissue fragments using a combination of an enzyme mix and agitation and then collecting the LSSC. Pharmaceutical preparations comprising LSSC are also provided.

公开(公告)号：US20240252548A1

公开(公告)日：2024-08-01

申请号：US18578959

申请日：2022-07-13

申请人： BRITECYTE INC.

发明人： Alla DANILKOVITCH

IPC分类号： A61K35/35 ,  A61K9/00 ,  A61K35/12 ,  A61K35/28 ,  A61P1/16 ,  A61P3/06

CPC分类号： A61K35/35 ,  A61K9/0019 ,  A61K35/28 ,  A61P1/16 ,  A61P3/06 ,  A61K2035/122

摘要： Disclosed are adipose matrices comprising devitalized, or vitalized, and partially delipidized adipose tissue. Disclosed are compositions comprising an adipose matrix comprising devitalized, or vitalized, and partially delipidized adipose tissue. Disclosed are compositions comprising an adipose matrix comprising devitalized, or vitalized, and partially delipidized adipose tissue and MSCs. Disclosed are methods of making any of the disclosed adipose matrices or compositions. Disclosed are methods of treating a subject having a metabolic liver disease, metabolic disease, ischemic wound, or inflammatory disease comprising administering to the subject a therapeutically effective amount of a composition disclosed herein. Disclosed are methods of decreasing cholesterol in a subject comprising administering to the subject a therapeutically effective amount of a composition disclosed herein. Disclosed are methods of decreasing lipids in the liver of a subject comprising administering to the subject a therapeutically effective amount of a composition disclosed herein.

公开(公告)号：US12023385B2

公开(公告)日：2024-07-02

申请号：US16483209

申请日：2018-02-08

申请人： DANA-FARBER CANCER INSTITUTE, INC.

发明人： Dennis Buckley ,  Georg Winter ,  Andrew J. Phillips ,  Timothy P. Heffernan ,  James Bradner ,  Justin Roberts ,  Behnam Nabet

IPC分类号： C12N15/90 ,  A61K35/12 ,  A61K35/407 ,  A61K38/46 ,  A61K47/55 ,  A61K48/00 ,  C12N9/10 ,  C12N9/22 ,  C12N9/90

CPC分类号： A61K48/0058 ,  A61K35/407 ,  A61K38/465 ,  A61K48/0025 ,  A61K48/0083 ,  C12N9/104 ,  C12N9/22 ,  C12N9/90 ,  C07K2319/20 ,  C07K2319/95 ,  C12Y502/01008

摘要： The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

公开(公告)号：US20240189353A1

公开(公告)日：2024-06-13

申请号：US18343693

申请日：2023-06-28

申请人： GENEIUS BIOTECHNOLOGY, INC.

发明人： Alfred E. SLANETZ

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K35/12 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K39/29 ,  C12N5/0783 ,  C12N7/00

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K9/0021 ,  A61K39/0008 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/245 ,  A61K39/292 ,  C12N5/0636 ,  C12N7/00 ,  A61K2035/124 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/585 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/999 ,  C12N2710/16034 ,  C12N2710/16234 ,  C12N2730/10134 ,  C12N2730/10171

摘要： The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit.

公开(公告)号：US11999971B2

公开(公告)日：2024-06-04

申请号：US18055312

申请日：2022-11-14

申请人： Vertex Pharmaceuticals Incorporated

发明人： Felicia J. Pagliuca ,  George Harb ,  Lillian Ye

IPC分类号： A61K35/39 ,  A61P5/50 ,  C12N5/071 ,  A61K35/12

CPC分类号： C12N5/0678 ,  A61K35/39 ,  A61P5/50 ,  A61K2035/126 ,  C12N2500/46 ,  C12N2501/11 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/19 ,  C12N2501/415 ,  C12N2501/999

摘要： Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

公开(公告)号：US20240174978A1

公开(公告)日：2024-05-30

申请号：US18363663

申请日：2023-08-01

申请人： Astellas Institute for Regenerative Medicine

发明人： Irina Klimanskaya

IPC分类号： C12N5/079 ,  A61K35/12 ,  A61K35/30 ,  A61K35/36 ,  A61K35/44 ,  A61K35/545 ,  C12N5/0793

CPC分类号： C12N5/0621 ,  A61K35/12 ,  A61K35/30 ,  A61K35/36 ,  A61K35/44 ,  A61K35/545 ,  C12N5/062 ,  C12N2500/32 ,  C12N2500/44 ,  C12N2501/01 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/235 ,  C12N2501/33 ,  C12N2501/60 ,  C12N2506/02

摘要： This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

公开(公告)号：US11992507B2

公开(公告)日：2024-05-28

申请号：US12161893

申请日：2007-01-23

申请人： Robert W. Mays ,  Robert J. Deans

发明人： Robert W. Mays ,  Robert J. Deans

IPC分类号： A61K35/28 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/485 ,  A61K31/52 ,  A61K31/661 ,  A61K35/12 ,  A61K35/30 ,  A61K35/407 ,  A61K35/44 ,  A61K35/48 ,  A61K35/50 ,  A61K35/51 ,  A61K35/545 ,  A61K38/13 ,  A61K45/06 ,  A61P25/00 ,  C12N5/074

CPC分类号： A61K35/50 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/485 ,  A61K31/52 ,  A61K31/661 ,  A61K35/12 ,  A61K35/28 ,  A61K35/30 ,  A61K35/407 ,  A61K35/44 ,  A61K35/48 ,  A61K35/51 ,  A61K35/545 ,  A61K38/13 ,  A61K45/06 ,  A61P25/00 ,  C12N5/0607 ,  A61K38/13 ,  A61K2300/00 ,  A61K35/545 ,  A61K2300/00

摘要： The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.

公开(公告)号：US11975027B2

公开(公告)日：2024-05-07

申请号：US17539155

申请日：2021-11-30

申请人： ImmunityBio, Inc.

发明人： Hans G. Klingemann ,  Barry J. Simon

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K9/50 ,  A61K38/20 ,  C12N5/0783 ,  A61K35/12

CPC分类号： A61K35/17 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/08 ,  A61K9/5068 ,  A61K38/2013 ,  C12N5/0646 ,  A61K2035/124 ,  A61K38/2013 ,  A61K2300/00 ,  A61K35/17 ,  A61K2300/00

摘要： Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.